HEALTH TECHNOLOGY

Amazon Launches Amazon HealthLake for Healthcare organizations

Amazon Web Services | December 09, 2020

Today at AWS re:Invent, Amazon Web Services, Inc. (AWS), an Amazon.com organization (NASDAQ: AMZN) declared Amazon HealthLake, a HIPAA-qualified help for healthcare and life sciences associations. Amazon HealthLake totals an association's finished information across different storehouses and unique organizations into a concentrated AWS information lake and naturally standardizes this data utilizing AI. The administration recognizes each bit of clinical data, labels, and lists occasions in a course of events see with normalized marks so it very well may be effortlessly looked, and structures the entirety of the information into the Fast Healthcare Interoperability Resources (FHIR) industry standard configuration for a total perspective on the wellbeing of individual patients and whole populaces. Accordingly, Amazon HealthLake makes it simpler for clients to question, perform investigation, and run AI to get important incentive from the recently standardized information. Associations, for example, healthcare frameworks, drug organizations, clinical analysts, wellbeing back up plans, and more can utilize Amazon HealthLake to help spot patterns and peculiarities in wellbeing information so they can make substantially more exact expectations about the movement of illness, the adequacy of clinical preliminaries, the exactness of protection charges, and numerous different applications.

 

As AI turns out to be more standard, organizations over each vertical business are attempting to apply it to their information to convey significant business esteem. Healthcare is applying AI to improve activities and patient consideration, with AWS clients like 3M, Anthem, AstraZeneca, Bristol Myers Squibb, Cerner, the Fred Hutchinson Cancer Research Center, GE Healthcare, Infor, Pfizer, and Philips grasping the cloud and AI to get more an incentive out of their immense information stashes. From family ancestry and clinical perceptions to analyses and prescriptions, healthcare associations are making gigantic volumes of patient data consistently with the objective of getting a full perspective on a patient's wellbeing and applying investigation and AI to improve care, break down populace wellbeing patterns, and improve operational proficiency. Be that as it may, clinical information is intricate and famous for being siloed, deficient, contradictory, and put away in on-premises frameworks spread over numerous areas. Getting this data collected and in the FHIR design is a head toward the objective of normalizing organized information, yet most of information stays unstructured and still should be labeled, recorded, and organized in sequential request to make the entirety of the information reasonable and ready to inquiry. Some healthcare associations assemble rule-based instruments to robotize the way toward changing unstructured information (e.g., clinical narratives, doctor notes, and clinical imaging reports) and labeling clinical data (e.g., conclusions, prescriptions, and techniques), yet these arrangements regularly come up short in light of the fact that the information should be standardized across dissimilar frameworks and on the grounds that the devices can't represent each conceivable variety in spelling, unintended mistakes, and linguistic blunders. Different associations utilize broadly useful optical character acknowledgment (OCR) programming to handle information sources, yet these apparatuses do not have the clinical mastery to be successful thus associations resort to manual information section by clinical experts which adds cost to the digitization cycle. Regardless of whether associations can total and structure their information, they actually need to construct their own investigation and AI applications to reveal connections in the information, find patterns, and make exact expectations. The expense and operational intricacy of accomplishing this work is restrictive to most associations; and thus, by far most of associations wind up passing up the undiscovered potential to utilize their information to improve the wellbeing of patients and networks

 

Amazon HealthLake offers clinical suppliers, wellbeing safety net providers, and drug organizations an assistance that unites and sorts out the entirety of their patient information, so healthcare associations can make more exact expectations about the soundness of patients and populaces. The new HIPAA-qualified help empowers associations to store, tag, file, normalize, question, and apply AI to dissect information at petabyte scale in the cloud. Amazon HealthLake permits associations to handily duplicate wellbeing information from on-premises frameworks to a protected information lake in the cloud and standardize each patient record across unique organizations consequently. Upon ingestion, Amazon HealthLake utilizes AI prepared to comprehend clinical phrasing to distinguish and label each bit of clinical data, record occasions into a timetable view, and improve the information with normalized marks (e.g., meds, conditions, analyze, methodology, and so forth) so this data can be effortlessly looked. For instance, associations can rapidly and precisely discover answers to their inquiries like, "How has the utilization of cholesterol-bringing down meds assisted our patients with hypertension a year ago?" To do this, clients can make a rundown of patients by choosing "Elevated Cholesterol" from a standard rundown of ailments, "Oral Drugs" from a menu of medicines, and pulse esteems from the "Circulatory strain" organized field – and afterward they can additionally refine the rundown by picking credits like time span, sex, and age. Since Amazon HealthLake additionally consequently structures the entirety of a healthcare association's information into the FHIR business design, the data can be effectively and safely shared between wellbeing frameworks and with outsider applications, empowering suppliers to team up more adequately and permitting patients liberated admittance to their clinical data.

 

“There has been an explosion of digitized health data in recent years with the advent of electronic medical records, but organizations are telling us that unlocking the value from this information using technology like machine learning is still challenging and riddled with barriers,” said Swami Sivasubramanian, Vice President of Amazon Machine Learning for AWS. “With Amazon HealthLake, healthcare organizations can reduce the time it takes to transform health data in the cloud from weeks to minutes so that it can be analyzed securely, even at petabyte scale. This completely reinvents what’s possible with healthcare and brings us that much closer to everyone’s goal of providing patients with more personalized and predictive treatment for individuals and across entire populations.”

 

By amassing, naming, ordering, and organizing all their information, Amazon HealthLake makes it simple for clients to question, examine, and use AI to figure out their information. Clients can utilize other AWS examination and AI administrations with Amazon HealthLake like Amazon QuickSight for intuitive dashboards and Amazon SageMaker for effectively building, preparing, and conveying custom AI models. For instance, healthcare associations can utilize Jupyter Notebook layouts in Amazon SageMaker to rapidly and effectively run examination for basic assignments like determination expectations, emergency clinic re-induction likelihood, and working room use figures. Healthcare and life science associations can utilize Amazon HealthLake to get a total perspective on patient and populace wellbeing, infer experiences utilizing investigation and AI, and find recently clouded connections and patterns.

 

Cerner Corporation, a global healthcare technology company, is focused on using data to help solve issues at the speed of innovation - evolving healthcare to enhance clinical and operational outcomes, help resolve clinician burnout, and improve health equity. "At Cerner we are committed to transforming the future of healthcare through cloud delivery, machine learning, and AI. Working alongside AWS, we are in a position to accelerate innovation in healthcare. That starts with data. We are excited about the launch of Amazon HealthLake and its potential to quickly ingest patient data from various diverse sources and transform the data to perform advanced analytics to unlock new insights and serve many of our initiatives across population health,” said Ryan Hamilton, SVP, Population Health, Cerner.

 

Ciox Health is a health technology company that is dedicated to improving U.S. health outcomes by transforming clinical data into actionable insights. “At Ciox, we work to enable greater health by improving the way health information is managed,” said Sasidhar Mukkamala, SVP of Data Management, Ciox Health. “Much of the health information that we ingest is unstructured, like notes and handwritten PDFs, and it is a challenge to find solutions that allow us to realize the full analytic value of that data. With 60 percent of the market share in risk adjustments, this is a huge opportunity. We are excited about getting started with Amazon HealthLake and its potential to help us meet this need and deliver better risk adjustments, predictions, billing, and much more, all informed by health data.”

 

Konica Minolta Precision Medicine (KMPM) is a life science company dedicated to the advancement of precision medicine to more accurately predict, detect, treat, and ultimately cure disease. "We are building a multi-modal platform at KMPM to handle a significant amount of health data inclusive of pathology, imaging, and genetic information. Amazon HealthLake will allow us to unlock the real power of this multi-modal approach to find novel associations and signals in our data. It will provide our expert team of data scientists and developers the ability to integrate, label, and structure this data faster, and discover insights that our clinicians and pharmaceutical partners require to truly drive precision medicine," said Kiyotaka Fujii, President of Global Healthcare, Konica Minolta.

 

Orion Health is a global, award-winning provider of health information technology, advancing population health and precision medicine solutions for the delivery of care across the entire health ecosystem. “At Orion Health, we believe that there is significant untapped potential to transform the healthcare sector by improving how technology is used and providing insights into the data being generated. We are pleased to find a like-minded company in AWS who, with Amazon HealthLake, is now taking the next step in using machine learning to help make sense of health data in a secure, complaint, and auditable way,” said Anne O'Hanlon, Product Director, Orion Health. “Data is frequently messy and incomplete, which is costly and time consuming to clean up. We are excited to work alongside AWS to deliver new ways for patients to interact with the healthcare system, supporting initiatives such as the 21st Century Cures Act designed to make healthcare more accessible and affordable, and Digital Front Door, which aims to improve health outcomes by helping patients receive the perfect care for them from the comfort of their home. Expanding the relationship we enjoy with AWS gives us an opportunity to innovate and explore new ways to deliver patient-centered healthcare and high quality health outcomes that help people live a healthier life.”

 

About Amazon Web Services

For 14 years, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud platform. AWS offers over 175 fully featured services for compute, storage, databases, networking, analytics, robotics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, virtual and augmented reality (VR and AR), media, and application development, deployment, and management from 77 Availability Zones (AZs) within 24 geographic regions, with announced plans for 18 more Availability Zones and six more AWS Regions in Australia, India, Indonesia, Japan, Spain, and Switzerland. Millions of customers—including the fastest-growing startups, largest enterprises, and leading government agencies—trust AWS to power their infrastructure, become more agile, and lower costs.

Spotlight

Healthcare providers are continuing to turn toward advanced technologies and the Internet of Things to improve care services, according to a new infographic by MedicoReach. The infographic examines the attributes of smart healthcare, barriers to smart healthcare adoption and provider response to these barriers.


Other News
FUTURE OF HEALTHCARE

Medicago Announces Publication of Phase 3 COVID-19 Vaccine Study Results in New England Journal of Medicine

Medicago | May 06, 2022

Medicago announced the publication of the results from the Phase 3 study of COVIFENZ®, COVID-19 vaccine recombinant, adjuvanted, in the New England Journal of Medicine. The Phase 3 trial studied the two-dose regimen of COVIFENZ® given 21 days apart versus placebo in over 24,000 subjects aged 18 and above. Common side effects in the vaccine group included injection site pain, headache, fatigue, fever, muscle aches, and chills. COVIFENZ® is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 in individuals 18 to 64 years of age. The safety and efficacy of COVIFENZ® in individuals younger than 18 years of age or 65 years and older have not been established. COVIFENZ® has not yet received approval in other jurisdictions. “We are proud to have our Phase 3 clinical trial published in the esteemed New England Journal of Medicine to be shared with the larger scientific community. Medicago’s scientific team has dedicated decades to the development of our proprietary plant-based vaccine manufacturing platform, and we are thrilled to see our results disseminated in this way. We hope that this exchange of research and knowledge will encourage and inspire future innovation in biomedical science and clinical practice.” Marc-André D’Aoust, Executive Vice President, Innovation, Development and Medical Affairs at Medicago COVIFENZ® was authorized for use by Health Canada on February 24, 2022. This is the first authorized COVID-19 vaccine developed by a Canadian-headquartered company, and the first that uses a plant-based protein technology. “The world needs a diverse range of vaccine options to continue to fight COVID-19, and we are proud to be able to contribute,” said Toshifumi Tada, CEO and President at Medicago. About Medicago Medicago is on a mission to help improve global public health using the power of plants. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare, Medicago is a pioneer in plant-based therapeutics. We are proudly rooted in Quebec, with manufacturing capacity in both Canada and the US. Our passionate and curious team of over 500 scientific experts and employees are dedicated to using our technology to provide rapid responses to emerging global health challenges, and to advancing therapeutics against life-threatening diseases worldwide. Medicago is an affiliated company of Mitsubishi Tanabe Pharma Corporation. About Mitsubishi Tanabe Pharma Corporation Mitsubishi Tanabe Pharma Corporation, the majority parent company of Medicago, is one of the large Japanese pharmaceutical companies, with its headquarters in Osaka, Japan. It positions vaccines as one of its key R&D areas and is also working to develop new modalities of vaccines. MTPC will further contribute to the prevention of infectious diseases which is one of the world’s important social issues, by delivering a new option of plant-based VLP vaccine as a new type of vaccine. MTPC is a member of Mitsubishi Chemical Holdings Group.

Read More

HEALTH TECHNOLOGY

Northwell Health and Aegis Ventures Launch Ascertain – Healthcare AI Company Creation Platform to Improve Quality and Access to Care

Northwell Health | April 13, 2022

Northwell Health, New York’s largest healthcare provider, and Aegis Ventures, a New York-based startup studio announced at their inaugural Healthcare AI Innovation Summit the finalization of definitive agreements to launch Ascertain, a joint company creation platform. Ascertain is a first-of-its-kind partnership that pairs a dynamic venture studio with one of the nation’s largest and most impactful health systems to develop and commercialize breakthrough healthcare AI companies that improve quality and access to care and close health equity gaps. Ascertain represents a novel, more targeted approach to the way entrepreneurs and healthcare systems collaborate to solve major healthcare challenges. The platform combines clinical and business leadership, expert technical and product teams, access to Northwell’s leading, diverse datasets, and capital resources within a single ecosystem – with a sole focus on building and validating effective solutions that can be rapidly brought to market. “Ascertain brings a unique structure, an innovative approach, and a compelling vision to create breakthrough healthcare AI companies that are set up for success. We are all driven by the idea that everyone deserves access to high-quality, affordable healthcare. Our aim is clear: to find new, cost-efficient ways to create and accelerate companies that deliver real, equitable solutions.” Michael Dowling, President and CEO of Northwell Health Ascertain has commenced the creation of its first portfolio companies in partnership with Northwell’s clinicians and administrators. One such collaboration is focused on bringing substantive improvements in maternal health, working hand-in-hand with Northwell’s recently launched Center for Maternal Health to develop new approaches to detecting and managing serious complications for expectant mothers and babies. Ascertain’s data science team has been working hand-in-hand with Northwell’s Maternal and Fetal Medicine team to examine tens of thousands of cases of preeclampsia, a hypertensive pregnancy complication that disproportionately affects Black mothers in the United States. Using cutting-edge data science techniques, the Ascertain team aims to deliver an AI solution that helps clinicians predict the risk of developing preeclampsia, enabling them to intervene earlier than previously possible. “Existing approaches to the detection of preeclampsia often occur too late in pregnancy, once the condition has begun to manifest. An important enabler for a solution to this challenge is predictive analytics, applying available knowledge of a patient's history to enable action far earlier with simple, yet life-saving, clinical interventions. We believe the AI solution Ascertain is currently developing will enable this,” shared Burt Rochelson, MD, Chief of Maternal Medicine at Northwell Health. “Aegis and Northwell’s multidisciplinary teams are pursuing innovation through a systematic approach that will bring validated solutions to patients more quickly and at a lower cost,” said Bill Schoenfeld, Aegis Ventures Chairman. “Our skillsets are extraordinarily complementary and enable us to address healthcare’s most entrenched quality, equity, and cost problems far more powerfully than either organization could alone.” Ascertain is preparing to launch multiple companies in 2022 that focus on maternal health, chronic disease detection and management, and next-generation AI tools. Ascertain’s Chairman Tom Manning shared, “Together, we’re paving a new way forward, a monumental step toward real, proven AI solutions that can bring impact to the world. It is a bold collaboration to drive AI-backed companies that save lives and resolve long-standing health inequities – and realize results that deliver something greater in healthcare.” Ascertain is committed to building exceptional teams that will embrace this unique opportunity to create unparalleled impact. To learn more about Ascertain or register your interest, please visit https://ascertain.com/. About Ascertain Ascertain is a revolutionary new partnership between Northwell Health, New York’s largest healthcare provider, and Aegis Ventures, a dynamic startup studio. This unique partnership assembles leading medical, technology, and business resources to create a first-of-its-kind company creation platform for healthcare innovation to address healthcare’s most challenging quality, equity, and cost problems. Ascertain brings $100M in seed-stage capital to bear in pursuit of a three-pronged approach to company creation: internal ideation, commercialization of scientific breakthroughs, and US market entry partnerships for global ventures. Ascertain creates companies that improve quality of care, patient experience, and long-standing health, placing patient needs at the center of every business model, technology solution, and product. About Northwell Health Northwell Health is New York State’s largest healthcare provider and private employer, with 23 hospitals, 830 outpatient facilities and more than 16,600 affiliated physicians. We care for over two million people annually in the New York metro area and beyond, thanks to philanthropic support from our communities. Our 77,000 employees – 18,900 nurses and 4,800 employed doctors, including members of Northwell Health Physician Partners – are working to change healthcare for the better. We’re making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. About Aegis Ventures Aegis Ventures is a next-generation startup studio that partners with entrepreneurs and industry leaders to originate, launch, and scale transformative companies. Our platform brings together market-shaping ideas, permanent growth capital, and ambitious individuals driven to solve major societal problems. We aim to build companies with the capacity for vast impact, with an initial focus on artificial intelligence and digital health. Within these verticals, Aegis seeks to create companies that leverage technology to better optimize tradeoffs between quality, access, and cost, focusing on innovations that promote seamless continuity of care, patient empowerment, and better-informed clinical decision-making.

Read More

FUTURE OF HEALTHCARE

Endonovo Therapeutics Signs Agreement with NAMSA to Develop Reimbursement Strategy for Endonovo Medical Products

Endonovo Therapeutics, Inc. | April 26, 2022

Endonovo Therapeutics, Inc. announced an agreement with NAMSA – a leading Global Contract Research Organization and medical device reimbursement specialist – as strategic advisors to develop in-patient and out-patient medical reimbursement strategies for Endonovo’s flagship PEMF product SofPulse®. “Engaging NAMSA as strategy advisors to develop and apply proven medical device reimbursement strategies is a huge advantage for Endonovo and our shareholders, according to Endonovo CEO Alan Collier. “NAMSA is a proven medical device development partner with relevant therapeutic know-how that is critical when seeking acceleration of reimbursement efforts and commercialization objectives,” he pointed out. NAMSA was founded in 1967 as a scientific research company and later transitioned into a Global CRO and Medtech (Medical Technologies) reimbursement specialist. Today, it has 1,000 strategic associates who provide Medtech reimbursement advisory expertise to more than 300 clients in 15 global regions. NAMSA offers a full continuum of reimbursement services for medical technologies. Their reimbursement consultants provide: payer relations, medical policy research, coverage advocacy, Healthcare Common Procedure Coding System Current Procedural Terminology code analysis/applications and health economic analysis. “Our team strives to bring impactful products like the Endonovo SofPulse into higher adoption. With this technology, and its favorable economics, there are multiple opportunities ahead for serving populations in need. We will work together with the Endonovo team to improve market access for this novel device in the very near term.”, Joseph Sierra, Director, Reimbursement Consulting, North America, NAMSA NAMSA provides strategic guidance and tactical support to fast-track medical device commercialization and to make an immediate impact on patient healthcare worldwide. NAMSA’s services have grown to include regulatory, reimbursement and quality consulting as well as clinical research. These additions have helped NAMSA to become the pre-eminent 100% medical device-focused Global CRO that offers proven strategic solutions throughout the full development continuum. NAMSA is the only US FDA ASCA accredited medical device biocompatibility laboratory in the world. This allows medical device sponsors to fast-track commercialization efforts, while achieving time and cost efficiencies in every major market of the world. Collier stated: “We are fortunate to be working directly with Joseph Sierra, at NAMSA. With over 10 years of reimbursement experience, and his proven track-record in developing successful medical device reimbursement strategies is exemplary and will be helpful in developing the path toward reimbursement for our main product SofPulse®. Joseph is an adjunct instructor at USC Masters of Health Administration Program, and his prior professional work includes successful stints with NeoFect USA and Medtronic Ltd. where he demonstrated a record of success leading roles in reimbursement programs, analysis, and strategies for their medical devices.” NAMSA’s reimbursement expertise and track-record in the introduction and adoption of medical devices into multiple medical specialties includes: orthopedics, cardiovascular surgery, general surgery, plastic surgery, neurology, robotic surgery and wound care. Collaborating with NAMSA on global reimbursement allows Endonovo to explore reimbursement for the U.S. medical markets as well as the European Union market adoption through SofPulse® medical CE Mark. Additional target markets would be Taiwan and other Asian countries. About Endonovo Therapeutics Inc. Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable Electroceuticals® therapeutic devices for pain relief, general wellness and wound curatives. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals® therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system disorders, including traumatic brain injury, acute concussions, post-concussion syndrome and multiple sclerosis. The Company's noninvasive Electroceutical® therapeutic device, SofPulse®, which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema. It also has CMS national coverage for the treatment of chronic wounds. The Company's current portfolio of preclinical-stage Electroceuticals® therapeutic devices addresses chronic kidney disease, liver disease, non-alcoholic steatohepatitis cardiovascular and peripheral artery disease and ischemic stroke. The Company's noninvasive, wearable Electroceuticals® therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

Read More

FUTURE OF HEALTHCARE

Ascensus Closes Newport Merger Agreement

Ascensus | April 11, 2022

Ascensus—whose technology and expertise help millions of people save for retirement, education, and healthcare—and Newport, the Walnut Creek, California-based retirement services provider—announced today that the two companies have closed their previously announced merger, the first step in their journey together as a combined organization. The union combines the capabilities and talents of two market leaders in tax-advantaged savings and related services, serving more than 15 million savers and overseeing more than $745 billion in assets under administration as of December 31, 2021. Together, the unified company employs more than 5,400 employees across the U.S. David Musto, president and chief executive officer of Ascensus, will serve as CEO of the combined company. Laura Ramanis, who has served as interim CEO of Newport since the announcement of the transaction last fall, and Kurt Laning, executive vice president of Newport Non-Qualified and Insurance Solutions, will join the Ascensus executive leadership team, reporting to Musto. "With today's announcement, Ascensus and Newport have taken an important step in our journey towards a stronger, unified company. Clients across our lines of business will benefit from our expanded capabilities—accelerated investments in technology, data analytics, and user experiences—and broadened expertise. And both Ascensus and Newport associates can look forward to new opportunities for personal growth and enhanced career development." Musto "Ascensus and Newport share a passion for helping people save for their futures and supporting the growth and success of our partners," said Ramanis. "We look forward to continuing that mission as a combined company." With industry-leading qualified and non-qualified retirement plan services, corporate and bank-owned life insurance (COLI and BOLI) practices, fiduciary and trust solutions, and other total rewards capabilities, Newport expands the services and expertise Ascensus provides to its clients and advisor partners. Newport's clients will benefit from greater access to unique tax-advantaged savings solutions across retirement, education, and health provided by Ascensus. The combined company's investments in technology, digital capabilities, and analytics will deliver enhanced value to clients, expand client relationships, and create even better outcomes for savers. Both the Ascensus and Newport brands remain in use at closing, with the Ascensus brand representing the unified company. "Our goal over the next several months is the successful unification of our company—built on the principle of 'best of the best' and our shared cultural attributes, and executed with the interests, quality, and stability of our client relationships foremost in mind," added Musto. "As a unified organization, Ascensus and Newport share a strong commitment to serving our clients and offering more—across the tax-advantaged retirement, education, and health savings expertise for which Ascensus is known, and capitalizing on Newport's well-established qualified and non-qualified retirement services, and fiduciary and COLI/BOLI capabilities as well." Evercore acted as exclusive financial advisor to Newport in connection with the transaction. Goldman Sachs Bank USA, SPC Financing Company LLC, and KKR Capital Markets LLC led the financing consortium. Simpson Thacher & Bartlett LLP acted as transactional counsel to Ascensus and Kirkland & Ellis LLP acted as financing counsel to Ascensus. Morgan Lewis & Bockius LLP acted as legal counsel to Newport. About Ascensus Ascensus helps millions of people save for what matters—retirement, education, and healthcare. Through co-branded, private-labeled, and other governmental partnerships, our technology, market insights, and business knowledge enhance the growth and success of our partners, their clients, and savers. Ascensus is a leading recordkeeping services provider, third-party administrator, and government savings facilitator in the United States. About Newport Headquartered in Walnut Creek, California, Newport is a leading retirement services provider that helps employers—and the advisors who serve them—prepare employees for a more financially secure retirement. The company has more than $150 billion in retirement assets under administration and more than $300 billion in corporate retirement and insurance assets. Newport maintains investment objectivity, fee transparency and a commitment to flexible, responsive service. Staffed by an exceptional team of nearly 1,500 retirement, insurance, and consulting professionals, the company provides retirement solutions tailored to the needs of employers of every size, from small businesses to the Fortune 1000.

Read More

Spotlight

Healthcare providers are continuing to turn toward advanced technologies and the Internet of Things to improve care services, according to a new infographic by MedicoReach. The infographic examines the attributes of smart healthcare, barriers to smart healthcare adoption and provider response to these barriers.

Resources